Mark Agulnik

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma”.

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Nature Communications(2022)10.1038/s41467-022-30496-0

N/A

5.2DataRank · unranked

198 citations

Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard Ferraro, Sherri Z. Millis +38 more

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990

N/A

4.8DataRank · unranked

160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

Evolving strategies for management of desmoid tumor

Cancer(2022)10.1002/cncr.34332

N/A

0.657DataRank · unranked

79 citations

Mark Agulnik, Richard F. Riedel

Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer

The Journal of Clinical Endocrinology & Metabolism(2025)10.1210/clinem/dgae512

N/A

0.345DataRank · unranked

9 citations

Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar, John C Morris +12 more

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors

medRxiv(2025)10.1101/2025.06.02.25328445

N/A

0DataRank · unranked

2 citations

Esteban Abella, Stefan Wieland, Thu‐Ha Nguyen, Sangeetha Srinivasan, M. Alečković +10 more

Underreporting of SMARCB1 alteration by clinical sequencing: Integrative patho-genomic analysis captured SMARCB1/INI-1 deficiency in a vulvar yolk sac tumor

Gynecologic Oncology Reports(2023)10.1016/j.gore.2023.101294

N/A

0DataRank · unranked

2 citations

Wenge Wang, Evita Sadimin, Lorna Rodrı́guez-Rodrı́guez, Mark Agulnik, Janet Yoon +4 more

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.11562

N/A

0DataRank · unranked

7 citations

Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark A. Dickson, Richard F. Riedel +10 more

A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas

Cancers(2020)10.3390/cancers12071873

N/A

0DataRank · unranked

57 citations

Keith M. Skubitz, Seth Maliske, Sarah L. Mott, Hilary Dietz, Angela C. Hirbe +11 more

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11531

N/A

0DataRank · unranked

1 citations

Shing M. Lee, Liner Ge, Mihaela Druta, Anthony P. Conley, Mary Louise Keohan +14 more